Johnson & Johnson (NYSE:JNJ) Given Average Recommendation of “Moderate Buy” by Brokerages

Posted by George Bondi on Jun 26th, 2026

Shares of Johnson & Johnson (NYSE:JNJ – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-seven ratings firms that are currently covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation and twenty have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $253.0435.

A number of equities research analysts recently weighed in on the company. Raymond James Financial upped their price target on Johnson & Johnson from $237.00 to $258.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Weiss Ratings cut Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, June 15th. Guggenheim upped their price target on Johnson & Johnson from $244.00 to $266.00 and gave the stock a “buy” rating in a report on Monday, April 20th. TD Cowen assumed coverage on Johnson & Johnson in a report on Wednesday, April 8th. They issued a “buy” rating and a $250.00 price target on the stock. Finally, Citigroup upped their price target on Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th.

View Our Latest Report on JNJ

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after buying an additional 3,731,074 shares during the last quarter. State Street Corp grew its holdings in Johnson & Johnson by 1.3% during the 4th quarter. State Street Corp now owns 133,869,843 shares of the company’s stock valued at $27,704,364,000 after buying an additional 1,663,782 shares during the last quarter. Auto Owners Insurance Co grew its holdings in Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after buying an additional 69,108,368 shares during the last quarter. Geode Capital Management LLC grew its holdings in Johnson & Johnson by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock valued at $11,967,947,000 after buying an additional 1,738,292 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $6,924,523,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Johnson & Johnson was highlighted as a top dividend-safe name, with multiple articles arguing that its reliable cash flows and long dividend track record make it an attractive holding for income-focused investors. One Stock to Own For Ultimate Dividend Safety
Positive Sentiment: The company advanced its cardiac ablation technology in Europe with the availability of its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, a reminder that JNJ continues to expand its medtech portfolio and commercial reach. Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform
Neutral Sentiment: Analysts are looking for a single-digit earnings increase when Johnson & Johnson reports second-quarter results in July, which suggests stable but not explosive near-term growth expectations. Johnson & Johnson Earnings Preview: What to Expect
Neutral Sentiment: Recent market commentary also noted JNJ rising while broader markets dipped, indicating investor preference for defensive stocks rather than a company-specific catalyst. Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $244.93 on Friday. The company has a market cap of $589.61 billion, a price-to-earnings ratio of 28.32, a price-to-earnings-growth ratio of 2.36 and a beta of 0.26. The stock has a 50 day simple moving average of $230.60 and a 200-day simple moving average of $229.25. Johnson & Johnson has a 12-month low of $151.01 and a 12-month high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were issued a $1.34 dividend. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s payout ratio is currently 61.97%.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.